Δημοσίευση στις 2018 Jun 15 στο PubMed: https://pubmed.ncbi.nlm.nih.gov/29907995/?from_term=tsioufis&from_sort=date&from_size=200&from_pos=88
J Clin Hypertens (Greenwich)
Search in PubMed
Search in NLM Catalog
Add to Search
There is an unmet need to prevent cardiovascular disease and chronic kidney disease development and progression worldwide. Losartan, the first angiotensin receptor blocker, was shown to exert significant cardioprotective and renoprotective effects in the LIFE (Losartan Intervention for Endpoint Reduction in Hypertension) and RENAAL (Reduction of Endpoints in NIDDM With the Angiotensin II Antagonist Losartan) trials. Losartan significantly prevented stroke and decreased serum uric acid levels and the rates of new-onset diabetes mellitus and atrial fibrillation. The present review discusses the LIFE (and its subanalyses) and RENAAL trials and the translation of their results to clinical practice. The place of losartan in the current guidelines for hypertension management is also discussed. Losartan still represents an efficacious, safe, and cost-effective therapeutic option in patients with hypertension who have left ventricular hypertrophy. Losartan is a useful antihypertensive agent for stroke prevention and in the management of patients with chronic kidney disease, atrial fibrillation, diabetes mellitus, albuminuria, and hyperuricemia.
albuminuria; atenolol; cardiovascular risk; diabetes mellitus; hypertension; left ventricular hypertrophy; losartan; stroke; uric acid.
©2018 Wiley Periodicals, Inc.
Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.
Am J Cardiol. 2005 Dec 1;96(11):1530-6. doi: 10.1016/j.amjcard.2005.07.061. Epub 2005 Oct 17.
Am J Cardiol. 2005.
Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Curr Med Res Opin. 2007 Feb;23(2):443-57. doi: 10.1185/030079906X167435.
Curr Med Res Opin. 2007.
Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL.
Curr Med Res Opin. 2004 Dec;20(12):1909-17. doi: 10.1185/030079904X13040.
Curr Med Res Opin. 2004.
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
J Am Coll Cardiol. 2005 Mar 1;45(5):712-9. doi: 10.1016/j.jacc.2004.10.068.
J Am Coll Cardiol. 2005.
Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension.
Clin Ther. 2006 Jun;28(6):832-48. doi: 10.1016/j.clinthera.2006.06.002.
Clin Ther. 2006.